Comparison of low dose vs standard dose abiraterone in prostate cancer patients
Phase 2
Recruiting
- Conditions
- Prostate cancer.Malignant neoplasm of prostate
- Registration Number
- IRCT20120618010057N3
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 64
Inclusion Criteria
Metastatic prostate cancer patients who are candidates for triplet therapy
Exclusion Criteria
Hormone resistant
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biochemical free survival. Timepoint: 3 months interval. Method of measurement: Prostate-Specific Antigen (PSA) test.
- Secondary Outcome Measures
Name Time Method